Enveric Biosciences FY2025 net loss climbs 25% to $4.0 million; cash-on-hand falls to $4.7 million

Reuters03-28

<a href="https://laohu8.com/S/ENVB">Enveric Biosciences</a> FY2025 net loss climbs 25% to $4.0 million; cash-on-hand falls to $4.7 million

Enveric published a Form 8-K reporting financial results and a corporate update.
Net loss attributable to stockholders was USD 4.0 million, up 25% from the prior-year quarter, and basic and diluted loss per share was USD 6.12.
Cash on hand was USD 4.7 million at quarter-end, and FY gross proceeds raised through offerings were USD 12.2 million.
Subsequent to year-end, the company raised approximately USD 1.5 million in January 2026 via a registered direct offering and approximately USD 1.45 million in February 2026 via an at-the-market offering.
Management said it is completing IND-supporting work for lead candidate EB-003 after an FDA response allowing streamlined plans for an IND submission, following completion of pre-IND dose range finding studies and CMC milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-013290), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622805348?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 05:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622805348","market":"fut","top_or_hot":-1,"title":"Enveric Biosciences FY2025 net loss climbs 25% to $4.0 million; cash-on-hand falls to $4.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ENVB\">Enveric Biosciences</a> FY2025 net loss climbs 25% to $4.0 million; cash-on-hand falls to $4.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Enveric published a Form 8-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> reporting financial results and a corporate update.\n        </li>\n<li>\n          Net loss attributable to stockholders was USD 4.0 million, up 25% from the prior-year quarter, and basic and diluted loss per share was USD 6.12.\n        </li>\n<li>\n          Cash on hand was USD 4.7 million at quarter-end, and FY gross proceeds raised through offerings were USD 12.2 million.\n        </li>\n<li>\n          Subsequent to year-end, the company raised approximately USD 1.5 million in January 2026 via a registered direct offering and approximately USD 1.45 million in February 2026 via an at-the-market offering.\n        </li>\n<li>\n          Management said it is completing IND-supporting work for lead candidate EB-003 after an FDA response allowing streamlined plans for an IND submission, following completion of pre-IND dose range finding studies and CMC milestones.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-013290), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enveric Biosciences FY2025 net loss climbs 25% to $4.0 million; cash-on-hand falls to $4.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnveric Biosciences FY2025 net loss climbs 25% to $4.0 million; cash-on-hand falls to $4.7 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-28 05:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ENVB\">Enveric Biosciences</a> FY2025 net loss climbs 25% to $4.0 million; cash-on-hand falls to $4.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Enveric published a Form 8-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> reporting financial results and a corporate update.\n        </li>\n<li>\n          Net loss attributable to stockholders was USD 4.0 million, up 25% from the prior-year quarter, and basic and diluted loss per share was USD 6.12.\n        </li>\n<li>\n          Cash on hand was USD 4.7 million at quarter-end, and FY gross proceeds raised through offerings were USD 12.2 million.\n        </li>\n<li>\n          Subsequent to year-end, the company raised approximately USD 1.5 million in January 2026 via a registered direct offering and approximately USD 1.45 million in February 2026 via an at-the-market offering.\n        </li>\n<li>\n          Management said it is completing IND-supporting work for lead candidate EB-003 after an FDA response allowing streamlined plans for an IND submission, following completion of pre-IND dose range finding studies and CMC milestones.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-013290), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL9l3DSb:1","article_id":"2622805348","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622805348","pubTimestamp":1774646786,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Enveric published a Form 8-K reporting financial results and a corporate update.Net loss attributable to stockholders was USD 4.0 million, up 25% from the prior-year quarter, and basic and diluted loss per share was USD 6.12.Cash on hand was USD 4.7 million at quarter-end, and FY gross proceeds raised through offerings were USD 12.2 million.Subsequent to year-end, the company raised approximately USD 1.5 million in January 2026 via a registered direct offering and approximately USD 1.45 million in February 2026 via an at-the-market offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retri","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ENVB":"Enveric Biosciences","EXSR":"Exchange Bank (Santa Rosa, CA)","BK4211":"区域性银行"},"translate_title":"Enveric Biosciences 2025财年净亏损攀升25%至400万美元；手头现金降至470万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENVB":0.9,"EXSR":0.9},"content_text":"Enveric Biosciences FY2025 net loss climbs 25% to $4.0 million; cash-on-hand falls to $4.7 million\n    \n\n\n          Enveric published a Form 8-K reporting financial results and a corporate update.\n        \n\n          Net loss attributable to stockholders was USD 4.0 million, up 25% from the prior-year quarter, and basic and diluted loss per share was USD 6.12.\n        \n\n          Cash on hand was USD 4.7 million at quarter-end, and FY gross proceeds raised through offerings were USD 12.2 million.\n        \n\n          Subsequent to year-end, the company raised approximately USD 1.5 million in January 2026 via a registered direct offering and approximately USD 1.45 million in February 2026 via an at-the-market offering.\n        \n\n          Management said it is completing IND-supporting work for lead candidate EB-003 after an FDA response allowing streamlined plans for an IND submission, following completion of pre-IND dose range finding studies and CMC milestones.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-013290), on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622805348","isCrawlerRequest":true}